Replies to post #261168 on Avid Bioservices Inc (CDMO)

[Protector]

jq1234, with hindsight you can say that, but WHERE are the posts (except mine, sunrise, tradero, golfho) that mentioned the possibility of the control arm outperforming from those you refer to in:

That's why everyone here has been wrong all along except the very few. Somehow those who had been wrong all along keep following the same logic.

At least I am glad the posters mentioned above were not part of those being wrong all along because we all mentioned the possibility of the control arm outperforming as the only remaining reasons.

And why would someone ANTICIPATE Docetaxel to outperform its stable performance since TWO DECADES now SPECIFICALLY in the SUNRISE trial. Isn't that weird as such?

The High Speed train goes from Brussels to Paris in 1H 10 times a day during 10 years and then someone predict that on data X hour Y it will take TWO hours. Wouldn't you think that to make such statement one could be part of creating the delay or just made a big time lucky guess?

[peregr]

I have lost total trust in the credibility of this management group especially the BOD. King is all we have. But now you are saying the FDA approved a flawed Phase 3 trial design? That this could have been biased by having more Asians in one arm versus another?

[nh]

That's unreasonable. Why SHOULD we have expected an anomaly in the control arm? You must mean we should have expect it since the P2 was sabotaged. I see. No, that's not what you meant, is it. OK, you meant we should have seen the anomaly due to patients receiving IO drugs that were approved during the trial. I mean, a lot of people figured it out immediately, in hindsight. Just look at the daily chart of PPHM and it's easy to see now. I guess a lot of people were just waiting for those approvals. Apparently. I guess those guys were geniuses or something.